Ie Ming Shih, MD, PhD

Professional Titles

• Richard W. TeLinde Distinguished Professor, Department of Gynecology and Obstetrics
• Director of TeLinde Gynecologic Pathology Laboratory
• Co-Director, Womens' Malignancy Program, Sidney Kimmel Comprehensive Cancer Center

Primary Academic Title

Professor of Gynecology and Obstetrics

Background

Centers and Institutes

• Ovarian Cancer Center
• Sidney Kimmel Comprehensive Cancer Center

Videos

• Innovation, Education, Collaboration

Recent News Articles and Media Coverage

• New Center to Take Multidisciplinary Approach to Endometriosis, Johns Hopkins Gynecology & Obstetrics Newsletter (Winter 2018)

Additional Academic Titles

Professor of Oncology, Professor of Pathology

Research Interests

Cancer Diagnostics, Cancer Pathogenesis, Molecular and Cellular Biology, Molecular Cancer Therapy

Lab Website

Gynecologic Pathology Laboratory - Lab Website

Research Summary

Dr. Shih's research team pursues out-of-the-box approaches at the very edges of knowledge to:

1.  elucidate the molecular/cellular/physiological landscapes of ovarian and uterine cancers,
2. understand the earliest events in their development and mechanisms of tumor evolution/dormancy and drug resistance,
3. deliver promises for better prevention, detection and treatment to women who have diseases or are at an increased risk to have these cancers.,
4. study the etiology of endometriosis and how to design a better classification system and interventions to treat endometriosis.

Please see www.gynecologycancer.org for details about Dr. Shih's research.

Lab Website:  Richard W. TeLinde Gynecologic Pathology Research Program

PubMed - Publications

https://www.ncbi.nlm.nih.gov/sites/myncbi/ie-ming.shih.1/bibliography/41146786/public/?sort=date&direction=ascending

Selected Publications

• Guan B, Rahmanto YS, Wu RC, Wang Y, Wang Z, Wang TL, Shih IM. ARID1A deletion in collaboration with PTEN deletion leads to ovarian tumorigenesis in mouse. J Natl Can Inst. 2014, Jun 4;106(7). pii: dju146. doi: 10.1093/jnci/dju146. Print 2014 Jul. PMCID: PMC4056776

• Kuhn E, Wu RC, Wu G, Guan B, Zhang J, Wang Y, Song L, Yuan X, Wei L, Roden RBS, Kuo KT, Nakayama K, Clarke B, Shaw P, Olvera N, Levine DA, Kurman RJ, Wang TL, Shih IM. Genome-wide analyses of uterine serous carcinoma identify pathway aberrations involving cyclin E-Fbxw7, PI3K and p53. J Natl Can Inst, 104:1503-1513, 2012. PMCID: PMC3692380

• Kurman RJ, Shih IM. The Dualistic Model of Ovarian Carcinogenesis. Revisited, Revised and Expanded.  Am J Pathol, 186:733-747, 2016. PMID: 27012190

• Rahmanto YS, Jung JG, Wu RC, Kobayashi Y, Heaphy CM, Meeker AK, Wang TL, Shih IM. Inactivating ARID1A tumor suppressor enhances hTERT transcription and maintains telomere length in cancer cells. J Biol Chem, 291:9690-9699, 2016. PMID: 26953344

• Yu Y,  Gaillard S, Jude MP, Huang TC, Pinto SM, Tessarollo NG, Zhang Z, Pandey A, Wirtz D, Ayhan A, Davidson B, Wang TL, Shih IM.  Inhibition of spleen tyrosine kinase potentiates paclitaxel-induced cytotoxicity in ovarian cancer cells by stabilizing microtubules. Cancer Cell, 28:82-96, 2015

Honors

• Consortium Planning Award, Department of Defense, Ovarian Cancer Research Program, 7/1/09
• Notch3 Signaling Pathway in the Ovarian Carcinoma, American Cancer Society, 7/1/08
• The Roles of HBXAP Gene in Ovarian Cancer, NCI/NIH, 4/1/08
• Nanobiosensing Method for Point Mutation Detection of Cancer, NCI/NIH, 4/1/08
• Pathogenesis of ovarian serous borderline tumors, NCI/NIH, 4/1/07
• Molecular diagnostics for malignant effusion, NCI/NIH, 12/1/04

Memberships

• American Association for Cancer Research
• United States and Canadian Association of Pathologists

Professional Activities

• Cancer Biomarkers Research Group, NCI/NIH, 1/1/08
• IMAT (R21/R33) New innovative technology in cancer, NCI/NIH, 1/1/02
• L (12)B Cancer Diagnostic & Treatment Study Section, NCI/NIH, 1/1/05 - 1/1/07
• Member of Cancer Molecular Pathobiology Study Section (CAMP), NCI/NIH, 1/1/06 - 1/1/11
• US DoD, Ovarian cancer research program, 1/1/05 - 1/1/09